These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1101 related articles for article (PubMed ID: 25203970)

  • 1. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV; Estrada SJ
    Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.
    Chahine EB; Karaoui LR; Mansour H
    Ann Pharmacother; 2014 Jan; 48(1):107-15. PubMed ID: 24259600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bedaquiline.
    Goulooze SC; Cohen AF; Rissmann R
    Br J Clin Pharmacol; 2015 Aug; 80(2):182-4. PubMed ID: 25702772
    [No Abstract]   [Full Text] [Related]  

  • 5. Bedaquiline as part of combination therapy in adults with pulmonary multi-drug resistant tuberculosis.
    Nguyen TV; Cao TB; Akkerman OW; Tiberi S; Vu DH; Alffenaar JW
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1025-37. PubMed ID: 27322153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TMC207 becomes bedaquiline, a new anti-TB drug.
    Palomino JC; Martin A
    Future Microbiol; 2013 Sep; 8(9):1071-80. PubMed ID: 24020736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multidrug-resistant tuberculosis and culture conversion with bedaquiline.
    Diacon AH; Pym A; Grobusch MP; de los Rios JM; Gotuzzo E; Vasilyeva I; Leimane V; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; De Paepe E; van Heeswijk RP; Dannemann B;
    N Engl J Med; 2014 Aug; 371(8):723-32. PubMed ID: 25140958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls.
    Kakkar AK; Dahiya N
    Tuberculosis (Edinb); 2014 Jul; 94(4):357-62. PubMed ID: 24841672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bedaquiline: a novel antitubercular drug for multidrug-resistant tuberculosis.
    Nagabushan H; Roopadevi HS
    J Postgrad Med; 2014; 60(3):300-2. PubMed ID: 25121373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bedaquiline. More data needed on this dangerous antitubercular drug.
    Prescrire Int; 2014 Oct; 23(153):232-4. PubMed ID: 25964964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bedaquiline for the treatment of pulmonary, multidrug-resistant tuberculosis in adults.
    Gras J
    Drugs Today (Barc); 2013 Jun; 49(6):353-61. PubMed ID: 23807939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diarylquinoline TMC207 for multidrug-resistant tuberculosis.
    Diacon AH; Pym A; Grobusch M; Patientia R; Rustomjee R; Page-Shipp L; Pistorius C; Krause R; Bogoshi M; Churchyard G; Venter A; Allen J; Palomino JC; De Marez T; van Heeswijk RP; Lounis N; Meyvisch P; Verbeeck J; Parys W; de Beule K; Andries K; Mc Neeley DF
    N Engl J Med; 2009 Jun; 360(23):2397-405. PubMed ID: 19494215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of tuberculosis: Focus on bedaquiline.
    Chan B; Khadem TM; Brown J
    Am J Health Syst Pharm; 2013 Nov; 70(22):1984-94. PubMed ID: 24173008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bedaquiline: a review of human pharmacokinetics and drug-drug interactions.
    van Heeswijk RP; Dannemann B; Hoetelmans RM
    J Antimicrob Chemother; 2014 Sep; 69(9):2310-8. PubMed ID: 24860154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
    Pym AS; Diacon AH; Tang SJ; Conradie F; Danilovits M; Chuchottaworn C; Vasilyeva I; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; Van Baelen B; van Heeswijk RP; Dannemann B;
    Eur Respir J; 2016 Feb; 47(2):564-74. PubMed ID: 26647431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort.
    Guglielmetti L; Le Dû D; Jachym M; Henry B; Martin D; Caumes E; Veziris N; Métivier N; Robert J;
    Clin Infect Dis; 2015 Jan; 60(2):188-94. PubMed ID: 25320286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATP Synthase, an Emerging Target in TB Drug Discovery: Review of SAR and Clinical Pharmacology of Diarylquinoline Inhibitors.
    Dhulap A; Banerjee P
    Curr Drug Targets; 2021; 22(11):1207-1221. PubMed ID: 33480344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bedaquiline for the treatment of drug-resistant tuberculosis.
    Bélard S; Heuvelings CC; Janssen S; Grobusch MP
    Expert Rev Anti Infect Ther; 2015 May; 13(5):535-53. PubMed ID: 25797824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis.
    Andries K; Verhasselt P; Guillemont J; Göhlmann HW; Neefs JM; Winkler H; Van Gestel J; Timmerman P; Zhu M; Lee E; Williams P; de Chaffoy D; Huitric E; Hoffner S; Cambau E; Truffot-Pernot C; Lounis N; Jarlier V
    Science; 2005 Jan; 307(5707):223-7. PubMed ID: 15591164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations.
    Hu M; Zheng C; Gao F
    Drug Des Devel Ther; 2016; 10():3983-3994. PubMed ID: 27994440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.